Skip to content
ANAVEX
ANAVEX
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
  • JOIN US
Search
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
  • JOIN US

Anavex Successfully Completes a Phase 1 Clinical Trial for ANAVEX 2-73

News ReleasesBy alessandroNovember 14, 2011Leave a comment

Hoboken, NJ — November 14, 2011 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced the successful completion of its Phase 1 single ascending dose (SAD) clinical trial of ANAVEX 2-73, the company’s lead drug candidate for the treatment of Alzheimer’s Disease (AD).  ANAVEX 2-73 is the first of a new class of oral…

ANAVEX® is a trademark of Anavex®Life Sciences Corp. - 2019 All Rights Reserved

Go to Top